Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $6.75.

A number of research analysts have recently commented on the stock. Citizens Jmp restated a “market outperform” rating and set a $8.00 price target on shares of Cellectis in a research report on Tuesday, April 14th. Jefferies Financial Group started coverage on shares of Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently bought and sold shares of the stock. Global Retirement Partners LLC bought a new position in Cellectis in the fourth quarter worth about $34,000. Acadian Asset Management LLC raised its stake in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares in the last quarter. Delaney Dennis R bought a new position in Cellectis in the third quarter worth about $68,000. Virtu Financial LLC bought a new position in Cellectis in the third quarter worth about $72,000. Finally, Millennium Management LLC raised its stake in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after buying an additional 22,080 shares in the last quarter. 63.90% of the stock is owned by institutional investors.

Cellectis Trading Up 1.3%

Shares of CLLS stock opened at $3.95 on Friday. The company’s fifty day simple moving average is $3.69 and its two-hundred day simple moving average is $4.01. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.62 and a quick ratio of 1.62. Cellectis has a 1 year low of $1.33 and a 1 year high of $5.48. The stock has a market capitalization of $396.34 million, a price-to-earnings ratio of -5.90 and a beta of 2.94.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Thursday, March 19th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%. The business had revenue of $15.50 million for the quarter, compared to the consensus estimate of $10.74 million.

Cellectis Company Profile

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.